FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds of formula I given below, or to their stereoisomers, tautomers or pharmaceutically acceptable salts thereof. R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and ring C are as defined by the invention formula. Wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration.
EFFECT: compounds of formula I are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
56 cl, 31 tbl, 649 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-PYRROLIDINYL-UREA, N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | 2013 |
|
RU2677667C2 |
| 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1N-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | 2015 |
|
RU2719489C2 |
| SUBSTITUTED COMPOUNDS OF PYRAZOLE[1,5-a]PYRIMIDINE AS TRK KINASE INHIBITORS | 2010 |
|
RU2584157C2 |
| BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOHUANIDINE COMPOUNDS, USEFUL FOR THE TREATMENT OF PAIN | 2013 |
|
RU2664541C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| TRIAZOLOPYRINE COMPOUNDS AS KINASE INHIBITORS PIM | 2012 |
|
RU2598846C2 |
| SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TROPOMYOSIN-RELATED KINASE INHIBITORS | 2009 |
|
RU2523544C2 |
| SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TRK KINASE | 2014 |
|
RU2666367C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| MELANOCORTIN RECEPTOR AGONISTS | 2007 |
|
RU2411240C2 |
